Elisabeth Specht Stovgaard

7PUBLICATIONS
13CO-AUTHORS
Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 25, 2023
ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations.

Bálint Cserni, Darren Kilmartin, Mark O'Loughlin

|Aug 12, 2022
Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial.

Elahe Shenasa, Elisabeth Specht Stovgaard, Maj-Britt Jensen

|Sep 10, 2021
Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer.

Darren Kilmartin, Mark O'Loughlin, Xavier Andreu

|May 24, 2021
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine.

Elisabeth S Stovgaard, Karama Asleh, Nazia Riaz

|May 03, 2020
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.

E S Stovgaard, M Bokharaey, K List-Jensen

|Jan 11, 2019
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.

Elisabeth Specht Stovgaard, Anne Dyhl-Polk, Anne Roslind

Pageof 2

Frequent Collaborators

2 joint publications

Simonetta Bianchi

2 joint publications

Maria Pia Foschini

2 joint publications

Caterina Marchiò

2 joint publications

Peter Regitnig